clinical trial · NCT07689539
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
Jiangxi Kvvit Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 360
Pancreatic CancerDN022150Chemotherapy
brief summary
This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy
started
Sep 1, 2026
primary completion
Jul 1, 2028
completion
Dec 1, 2028
last updated
Jul 8, 2026
detailed description
This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy
official title
A Phase 3, Multicenter, Open-Label, Randomized, Controlled Trial of DN022150 Monotherapy Versus Investigator's Choice Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol